Cents and Sensibility - Kimberly and Friends' Consortium Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mr. Fortune who wrote (77027)	2/18/2000 12:21:00 PM
From: KevinMark	Read Replies (1) of 108040

BPRX $2 pharmaceutical company that's next! I keep buying on every dip. Coverage by Robertson Stevens. P/E ratio of 14 and a chart ready for breakout on a moments notice. bigcharts.com Bradley Pharmaceuticals Ticker: BPRX Page 1 of 10 Complete Financials: September 1999 Exchange NASD FY END DEC ISSUE DATA (02/11/00) PER SHARE DATA RATIOS Price $ 2.44 EPS (TTM) $ 0.17 P/E (TTM) 14.43 52W High $ 3.00 Div. Rate $ 0.00 Yield 0.00 % 52W Low $ 1.00 Book Value $ 1.76 Price/Book 1.39 Shrs Out 8.63 Mil Cash $ 0.06 ROE (TTM) 9.90 % Float 5.10 Mil Rev (TTM) $ 2.36 ROA (TTM) 6.53 % Mon. Vol 2.09 Mil Curr. Ratio 1.09 Beta -0.36 LT Dbt/Eqty 0.01 BRIEF: BPRX manufactures and markets OTC and prescription pharmaceutical and health related products, such as dermatological, nutritional, respiratory, personal hygiene & internal medicine brands. For the 9 months ended 9/30/99, sales rose 30% to $13.5M. Net income totalled $565K, up from $118K. Revenues reflect gains from Doak Dermatologics' products. Earnings reflect the change of sales mix to products that carry higher profit percentage.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next